Evidence map›Paper›PMID 35932158›Full record

Trial reportInternational journal of geriatric psychiatry2022

Effects of an essential amino acid mixture on behavioral and psychological symptoms of dementia and executive function in patients with Alzheimer's disease: A double-blind, randomized, placebo-controlled exploratory clinical trial.

Michihiro Takada, Shin Tanaka, Koh Tanaka, Tamao Tsukie, Masako Tsukamoto-Yasui, Katsuya Suzuki, Yasushi Noguchi, Akira Imaizumi, Makoto Ishii, Takeshi Ikeuchi

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of geriatric psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Michihiro TakadaAjinomoto Co., Inc., Tokyo, Japan.
Shin TanakaMishima Hospital, Niigata, Japan.
Koh TanakaMishima Hospital, Niigata, Japan.
Tamao TsukieDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Masako Tsukamoto-YasuiAjinomoto Co., Inc., Tokyo, Japan.
Katsuya SuzukiAjinomoto Co., Inc., Tokyo, Japan.
Yasushi NoguchiAjinomoto Co., Inc., Tokyo, Japan.
Akira ImaizumiAjinomoto Co., Inc., Tokyo, Japan.
Makoto IshiiAjinomoto Co., Inc., Tokyo, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Ajinomoto (Japan) · JPAjinomoto (United States) · USNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing number of dementia patients has become a global social problem. Amino acids are known to be used as precursors of neurotransmitters in the brain. Amino acid mixtures as a supplement may be used as a solution to Alzheimer's symptoms. This exploratory study evaluated the efficacy and safety of a mixture containing nine essential amino acids on behavioral and psychological symptoms of dementia (BPSD) and cognitive function in patients with Alzheimer's disease (AD).

designWe conducted a double-blind, randomized, placebo-controlled trial to evaluate the intervention effects of nine essential amino acid mixture for 28 days. A total of 36 patients with AD were enrolled in Japan. BPSD and cognitive function were evaluated by the Neuropsychiatric Inventory-12 item (NPI-12; the primary endpoint), Mini-Mental State Examination (MMSE), Trail Making Test A (TMT-A), Trail Making Test B (TMT-B), Frontal Assessment Battery (FAB), and Clinical Dementia Rating Scale (CDR).

resultsCompared with placebo, the amino acid mixture did not improve NPI-12, MMSE, TMT-A and B or CDR scores. However, the analysis of covariance revealed improved FAB scores in the amino acid mixture group as a secondary endpoint. There were four subjects with adverse events in each group.

conclusionsOur results did not show a beneficial effect of the mixture containing nine essential amino acids on BPSD as a primary endpoint; however, it may improve executive function in patients with AD.

Indexed as

Alzheimer DiseaseAmino AcidsAmino Acids, EssentialCognitionDouble-Blind MethodExecutive FunctionHumansAmino AcidsAmino Acids, EssentialAlzheimer's diseaseessential amino acidsexecutive functionFrontal Assessment Battery

Identifiers

PMID35932158
PMCPMC9544995
OpenAlexW4286210007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.